Phase II study of carboplatin/pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A)

Phase II study of carboplatin/pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A) - Phase II of CBDCA/PEM/BEV for NSCLC with carcinomatous pleuritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006243

Enrollment

Registered

2011-10-01

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer (non-squamous cell carcinoma)

Interventions

carboplatin/pemetrexed/bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed NSCLC (non-squamous cell carcinoma) 2. Clinical stage IV or post-operative recurrence 3. Massive pleural effusion including malignant cells that requires tube drainage. 4. Chemotherapy naive except for EGFR-TKI 5. Aged over 20 years old with performance status 0-2 6. With addequate organ functions 7. With written informed consent

Exclusion criteria

Exclusion criteria: 1. Clinically ineligible interstitial pneumonitis 2. Episode of hemoptysis 3. With brain metastasis, or tumor with large vessel invation or cavity formation 4. With active gastrointestinal ulcer 5. With severe comorbidities 6. With inadequate conditions judged by the attending physician

Design outcomes

Primary

Measure	Time frame
The rate of controlled pleural effusion at 8 weeks	—

Countries

Japan

Contacts

Public ContactKazuhiro Usui

Kanto Medical Center NTT-EC Division of Respirology and Chest Surgery

usui@east.ntt.co.jp03-3448-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026